Antitumor activity of edotecarin in breast carcinoma models
Marina Ciomei(Nerviano Medical Sciences), Enrico Pesenti, Nadia Amboldi(University of Pavia), Rosa Giavarini(Nerviano Medical Sciences), Valter Croci(Nerviano Medical Sciences), Fabio Stellari(Chiesi Foundation)
Cited by 13
Related Papers
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
|Proceedings of the National Academy of Sciences|1995|205
The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
|Molecular Oncology|2014|156
Identification of <i>N</i>,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor
|Journal of Medicinal Chemistry|2009|128
Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury
|Molecular Cancer Therapeutics|2017|93